Core Viewpoint - The article discusses the importance of identifying the true responsibility and value of companies in the context of ESG (Environmental, Social, and Governance) governance, particularly through the newly released ESG-V rating list for listed companies in Jiangsu Province, which evaluates 621 companies to provide insights into their sustainable capabilities and investment values [1][2]. Group 1: ESG-V Rating System - The ESG-V rating system incorporates four dimensions: Environment (E), Social (S), Governance (G), and Value (V), aiming to provide a dual perspective of sustainability and investment potential for responsible investing [2][8]. - The top-rated companies, including Heng Rui Medicine, Huatai Securities, and Yuyue Medical, received the highest AAA rating, showcasing strong compliance and stable value characteristics [2][3]. Group 2: Industry Insights - The majority of high-rated companies share common traits such as mature governance structures, clear profit models, and stable value creation, with notable examples in the pharmaceutical and financial sectors [3][4]. - The overall distribution of ratings shows that 43% of companies are rated BBB or above, indicating a foundational balance between environmental, social, governance, and value dimensions among Jiangsu's listed companies [3][4]. Group 3: State-Owned Enterprises Performance - There is a noticeable performance divergence among state-owned enterprises, with some like Jiangsu Bank excelling in governance and value dimensions, while others lag in transparency and environmental management [4]. - The rating distribution reveals a "spindle-shaped" structure, with over 60% of companies rated between BB and A, indicating that many are still in the middle stage of establishing responsible governance [4][5]. Group 4: Future Implications - The ESG-V rating list serves as a lens to observe the ongoing journey of companies in Jiangsu towards green transformation and capital recognition, emphasizing the need for sustainable institutional foundations and rational market pricing for long-term value [8].

Core Insights - Yuyue Medical has integrated several health devices, including blood glucose meters, blood pressure monitors, and ventilators, with Ant Group's health management system, allowing automatic synchronization of monitoring data to users' personal health records for better health management [1] - The company has launched AI smart assistants such as "Yuyue Anai Sugar," "Yuyue Breathing Steward," and "Yuyue Blood Pressure Steward," which provide personalized health management advice based on user health data through the Ant Group application [1] - For the period from January to September 2025, Yuyue Medical reported a revenue of 6.545 billion yuan, representing a year-on-year increase of 8.58% (adjusted), while the net profit attributable to shareholders decreased by 4.28% (adjusted) to 1.466 billion yuan [1]

要闻速递 1、央行：建议发挥增量政策和存量政策集成效应 把握好政策实施的力度、节奏和时机 中国人民银行货币政策委员会2025年第四季度（总第111次）例会于12月18日召开。会议研究了下阶段货币政策主要思路， 建议发挥增量政策和存量政策集成效应，综合运用多种工具，加强货币政策调控，根据国内外经济金融形势和金融市场运 行情况，把握好政策实施的力度、节奏和时机。保持流动性充裕，使社会融资规模、货币供应量增长同经济增长、价格总 水平预期目标相匹配，促进社会综合融资成本低位运行。强化央行政策利率引导，完善市场化利率形成传导机制，发挥市 场利率定价自律机制作用，加强利率政策执行和监督。从宏观审慎的角度观察、评估债市运行情况，关注长期收益率的变 化。畅通货币政策传导机制，提高资金使用效率。增强外汇市场韧性，稳定市场预期，防范汇率超调风险，保持人民币汇 率在合理均衡水平上的基本稳定。评：明年的政策肯定是有的，只是需要等待一个契机，1月是一个重要节点，或许会有大 家期待的货币动作出现。如果落地了，市场整体的流动性会进一步改善，市场机会也会更多。 2、央行：加强对扩大内需、科技创新、中小微企业等重点领域的金融支持 中国人民银行 ...

Core Insights - The article highlights the significant growth and development of the MEMS (Micro-Electro-Mechanical Systems) industry in China, particularly through the achievements of Minxin Co., which has become a leader in MEMS sensors, producing 100 million sensors monthly and accumulating over 5 billion units shipped since its inception in 2007 [1][2]. Group 1: Company Development - Minxin Co. has evolved from a startup in 2007, when there were no domestic MEMS wafer foundries, to a leading MEMS chip company in China, achieving a revenue share of 47.61% from MEMS acoustic sensors in 2024 [1][3]. - The company has expanded its product matrix to include acoustic sensors, pressure sensors, inertial sensors, and posture sensors, with global rankings of fourth in MEMS microphones and third in MEMS acoustic sensor chip shipments [3][5]. Group 2: Product Strategy - The company aims to produce world-class products, with ongoing development of high-performance MEMS microphones and sensors for emerging markets such as humanoid robots and AR/VR applications [3][5]. - Minxin Co. emphasizes the importance of continuous R&D investment, with a planned R&D expenditure of over 80 million yuan in 2024, representing 16.01% of its revenue [5][6]. Group 3: Customer Relationships - The company collaborates with high-profile clients like Samsung, Xiaomi, and OPPO, focusing on building relationships that allow for mutual growth and high-quality product development [5][6]. - Minxin Co. recognizes that the value of its customers directly influences its own value, driving the company to invest heavily in assets to meet the quality and delivery expectations of premium clients [6][7]. Group 4: Industry Positioning - Minxin Co. has played a pivotal role in establishing the MEMS production capabilities in China, contributing to the creation of the first MEMS wafer fab through collaboration with state initiatives [7][8]. - The company aims to transition from being a participant in the industry chain to becoming an ecosystem builder, offering a comprehensive range of sensors for various applications [7][8]. Group 5: Future Outlook - The company has a clear strategic plan for the next five years, focusing on technology reserves in emerging fields like humanoid robots and IoT, as well as pursuing mergers and acquisitions to avoid homogenization in competition [8]. - Minxin Co. is committed to strengthening its R&D innovation, expanding its product categories, and targeting top-tier clients to become a global leader in MEMS solutions [8].

Core Viewpoint - Jiangsu Yuyue Medical Equipment Co., Ltd. has announced the initiation of foreign exchange hedging business, authorized management to exercise decision-making power for 12 months, and provided a feasibility analysis report for this business [1]. Group 1 - The sixth board of directors held a temporary meeting on December 24, 2025, to review and approve the proposal for foreign exchange hedging business [1]. - The meeting was conducted in accordance with the Company Law of the People's Republic of China and the company's articles of association, with all nine directors present and voting unanimously in favor [1]. - The board authorized the management to make decisions regarding the foreign exchange hedging business, with the finance department responsible for the specific operations [1]. Group 2 - The feasibility analysis report for the foreign exchange hedging business was also approved during the meeting, providing a basis for decision-making [1]. - Detailed information regarding the foreign exchange hedging business can be found in the announcement published on December 25, 2025, on various financial news platforms [2].

Core Viewpoint - Yuyue Medical announced the approval of a proposal to conduct foreign exchange hedging business during the fifteenth temporary meeting of its sixth board of directors [2] Group 1 - The board of directors approved the proposal regarding the company's foreign exchange hedging activities [2]

Core Viewpoint - Yuyue Medical (SZ 002223) announced a temporary board meeting on December 24, 2025, to discuss the feasibility report on foreign exchange hedging business [1] Group 1: Company Financials - For the first half of 2025, Yuyue Medical's revenue composition is as follows: respiratory therapy solutions accounted for 35.93%, clinical instruments and rehabilitation solutions for 24.35%, home health testing solutions for 21.77%, blood glucose management and POCT solutions for 14.48%, and emergency solutions and others for 2.92% [1] - As of the report, Yuyue Medical's market capitalization is 36.9 billion yuan [1]

Core Viewpoint - The company aims to mitigate foreign exchange and interest rate fluctuation risks by engaging in foreign exchange hedging activities, involving currencies such as USD and EUR [1] Group 1: Hedging Activities - The company and its subsidiaries plan to conduct foreign exchange hedging business, which includes forward foreign exchange contracts and foreign exchange swaps [1] - The maximum transaction amount at any point during the validity period will not exceed 300 million USD or its equivalent in RMB [1] - The upper limit for the business margin is set at 20 million USD or its equivalent in RMB, with a validity period of 12 months [1] Group 2: Funding and Approval - The funding for these activities will come from the company's own and other legal sources [1] - The board of directors has approved this matter, and it does not require shareholder meeting deliberation, thus not constituting a related party transaction [1] Group 3: Risk Management - The company has acknowledged market and liquidity risks associated with these activities and has established corresponding control measures [1]

证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-049 江苏鱼跃医疗设备股份有限公司 关于开展外汇套期保值业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1、公司及控股子公司拟开展的产品主要为外汇套期保值产品，自公司第六届董事 会第十五次临时会议审议通过之日起12个月内任一时点的交易金额（含前述投资的收益 进行再投资的相关金额）不超过3亿美元或等值人民币，相关业务保证金上限为2000万 美元或等值人民币。本次投资以规避和防范汇率风险为目的，资金使用安排合理，不会 影响公司主营业务的发展。交易场所为经有关政府部门批准、具有外汇套期保值业务经 营资质的金融机构。 2、审议程序：本次关于《公司开展外汇套期保值业务》的议案已经公司第六届董 事会审计委员会2025年第六次会议、第六届董事会第十五次临时会议审议通过。本事项 在董事会审批权限内，无需提交股东会审议。 3、风险提示：公司及控股子公司拟开展与日常经营相关的外汇套期保值业务主要 是为了降低市场波动对公司经营及损益带来的影响，但也可能存在市场风险、流动性风 险、信用风险、 ...

江苏鱼跃医疗设备股份有限公司 关于开展外汇套期保值业务的可行性分析报告 一、开展外汇套期保值业务概述 （一）开展外汇套期保值业务的目的 鉴于近期国际经济、金融环境波动频繁等多重因素的影响，人民币汇率波动的不确 定性增强，为防范汇率及利率波动风险，降低市场波动对江苏鱼跃医疗设备股份有限公 司（以下简称"公司"）经营及损益带来的影响，公司拟开展与日常经营相关的外汇套 期保值业务。 公司及控股子公司开展外汇套期保值业务投入的资金来源为自有资金、债务融资以 及公司通过法律法规允许的其他方式筹集的资金，不涉及募集资金。 5、外汇套期保值业务授权 本次投资不会影响公司主营业务的发展，公司资金使用安排合理。根据相关会计准 则，本次投资符合套期保值相关规定。 （二）开展外汇套期保值业务的情况 1、外汇套期保值涉及币种及业务品种 公司及控股子公司拟开展的外汇套期保值业务只限于从事与公司生产经营所使用 的主要结算货币相同的币种（主要外币币种有美元、欧元等），在境内外商业银行办理 的以规避和锁定汇率及利率风险和成本为目的的交易，包括远期结售汇、外汇掉期、外 汇期权等外汇衍生产品业务。结合日常业务需要，公司及控股子公司拟开展的产品主 ...